Logo image of CELZ

CREATIVE MEDICAL TECHNOLOGY (CELZ) Stock Price, Forecast & Analysis

USA - NASDAQ:CELZ - US22529Y4089 - Common Stock

3.17 USD
-0.1 (-3.06%)
Last: 10/31/2025, 8:00:00 PM
3.18 USD
+0.01 (+0.32%)
After Hours: 10/31/2025, 8:00:00 PM

CELZ Key Statistics, Chart & Performance

Key Statistics
Market Cap8.18M
Revenue(TTM)6.00K
Net Income(TTM)-5765600
Shares2.58M
Float2.55M
52 Week High6.9
52 Week Low1.69
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.18
PEN/A
Fwd PEN/A
Earnings (Next)11-06 2025-11-06
IPO2009-05-01
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


CELZ short term performance overview.The bars show the price performance of CELZ in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40

CELZ long term performance overview.The bars show the price performance of CELZ in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20 -25

The current stock price of CELZ is 3.17 USD. In the past month the price decreased by -2.01%. In the past year, price decreased by -21.14%.

CREATIVE MEDICAL TECHNOLOGY / CELZ Daily stock chart

CELZ Latest News, Press Relases and Analysis

CELZ Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 23.07 385.18B
AMGN AMGEN INC 13.68 160.66B
GILD GILEAD SCIENCES INC 14.63 148.64B
VRTX VERTEX PHARMACEUTICALS INC 25.12 109.11B
REGN REGENERON PHARMACEUTICALS 14.48 69.08B
ALNY ALNYLAM PHARMACEUTICALS INC 350.8 59.78B
ARGX ARGENX SE - ADR 61.04 50.39B
INSM INSMED INC N/A 40.08B
ONC BEONE MEDICINES LTD-ADR 5.01 34.10B
NTRA NATERA INC N/A 27.30B
BNTX BIONTECH SE-ADR N/A 24.98B
BIIB BIOGEN INC 9.22 22.62B

About CELZ

Company Profile

CELZ logo image Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.

Company Info

CREATIVE MEDICAL TECHNOLOGY

211 E. Osborn Rd.

Phoenix ARIZONA US

Employees: 4

CELZ Company Website

CELZ Investor Relations

Phone: 14803992822

CREATIVE MEDICAL TECHNOLOGY / CELZ FAQ

What does CREATIVE MEDICAL TECHNOLOGY do?

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The company is headquartered in Phoenix, Arizona and currently employs 4 full-time employees. The company went IPO on 2009-05-01. The firm conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.


What is the stock price of CREATIVE MEDICAL TECHNOLOGY today?

The current stock price of CELZ is 3.17 USD. The price decreased by -3.06% in the last trading session.


Does CREATIVE MEDICAL TECHNOLOGY pay dividends?

CELZ does not pay a dividend.


What is the ChartMill technical and fundamental rating of CELZ stock?

CELZ has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Can you provide the sector and industry classification for CREATIVE MEDICAL TECHNOLOGY?

CREATIVE MEDICAL TECHNOLOGY (CELZ) operates in the Health Care sector and the Biotechnology industry.


Can you provide the number of employees for CREATIVE MEDICAL TECHNOLOGY?

CREATIVE MEDICAL TECHNOLOGY (CELZ) currently has 4 employees.


Can you provide the market cap for CREATIVE MEDICAL TECHNOLOGY?

CREATIVE MEDICAL TECHNOLOGY (CELZ) has a market capitalization of 8.18M USD. This makes CELZ a Nano Cap stock.


CELZ Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to CELZ. When comparing the yearly performance of all stocks, CELZ is a bad performer in the overall market: 76.63% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CELZ Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to CELZ. No worries on liquidiy or solvency for CELZ as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CELZ Financial Highlights

Over the last trailing twelve months CELZ reported a non-GAAP Earnings per Share(EPS) of -3.18. The EPS increased by 21.48% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -81.15%
ROE -84.45%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%56.76%
Sales Q2Q%-100%
EPS 1Y (TTM)21.48%
Revenue 1Y (TTM)-71.43%

CELZ Forecast & Estimates

7 analysts have analysed CELZ and the average price target is 20.4 USD. This implies a price increase of 543.53% is expected in the next year compared to the current price of 3.17.

For the next year, analysts expect an EPS growth of 17.52% and a revenue growth -100% for CELZ


Analysts
Analysts82.86
Price Target20.4 (543.53%)
EPS Next Y17.52%
Revenue Next Year-100%

CELZ Ownership

Ownership
Inst Owners2.78%
Ins Owners0.49%
Short Float %2.05%
Short Ratio1.02